Therefore, our results suggest that the therapeutic targeting for Nrf2-HO-1 signaling attenuates the progression of renal fibrosis associated with diabetic nephropathy, which is manifested by the PI3K/Akt/GSK-3β pathway. The gene discussed is GSK3B; the disease is diabetic kidney disease.